Why CJC-1295 No DAC Research Matters in Wholesale Peptide Sourcing

CJC-1295 No DAC research matters to a wholesale buyer for one very practical reason: the compound sits inside a naming family where two structurally different molecules share almost the same name, and the only thing separating a correctly labeled vial from a mislabeled one is analytical documentation tied to the specific lot in your hands. For a business building a research peptide catalog, that turns a chemistry question into a procurement question. The literature tells you why researchers request the compound; the certificate of analysis tells you whether what arrived is actually it. Only one of those is under your supplier's control — and that is the one you should be evaluating.

Everything below is written for business buyers. All compounds discussed are research use only, not for human consumption, and nothing here describes use in people.

The molecule behind the abbreviation

CJC-1295 without DAC is a synthetic analogue built on the first 29 amino acids of growth hormone-releasing hormone — the fragment commonly referenced in the literature as GRF 1-29. Research describes several amino acid substitutions in this analogue that improve resistance to enzymatic breakdown compared with the unmodified fragment, which is why it appears so often in growth-axis signaling studies rather than the native sequence.

'DAC' stands for drug affinity complex: a chemical group added to the peptide that studies describe as binding to serum albumin, substantially extending how long the molecule remains in circulation in the models studied. The 'No DAC' version omits that group entirely. Research characterizes it as short-acting by comparison, which is precisely why some study designs call for it — investigators looking at pulsatile signaling behavior generally do not want a long-circulating analogue in the system.

That is the whole distinction, and it is not cosmetic. The two versions differ in molecular weight, in analytical retention behavior, in handling characteristics, and in cost to manufacture. They are not interchangeable, and a supplier treating them as interchangeable is telling you something important about how the rest of their catalog is managed.

Why the naming overlap is a supply-chain problem

Walk through the sector and you will find the same molecule sold under at least three labels: CJC-1295 No DAC, Mod GRF 1-29, and modified GRF 1-29. Meanwhile CJC-1295 with DAC is frequently listed as simply 'CJC-1295,' with the DAC status buried in a product description or absent altogether. The result is a category where a buyer can order in good faith and receive something structurally different from what the purchase order said.

For a reseller, clinic, or telehealth operator stocking research compounds, the consequences are procedural rather than dramatic. Your customer compares your label against a published sequence and molecular weight and finds a mismatch. You cannot resolve the dispute because your supplier issued a generic product sheet instead of a lot-specific analysis. You eat the return, or worse, you carry inventory you cannot honestly describe. None of this is exotic — it is the ordinary friction of buying from a supplier who does not test and publish per batch.

The fix is unglamorous: insist on documentation that names the exact molecule, reports its identity analytically, and ties both to the lot number printed on the vial you received. A supplier that can produce this on demand for CJC-1295 No DAC 10mg can almost certainly produce it across the rest of the catalog too.

What analytical testing actually proves — and what it does not

Buyers often treat a purity percentage as the whole answer. It is not. Understanding what each method establishes is what lets you read a COA critically instead of accepting it as decoration.

HPLC purity reports the proportion of the sample that resolves as the primary peak against everything else detected. A 99%-plus result is a strong statement about how little else is in the vial. It is not, by itself, a statement about what the main peak is.

Mass spectrometry addresses identity. It confirms the molecular weight of the primary component, which is the check that separates CJC-1295 No DAC from its DAC-bearing relative — the added complex changes the mass in a way that a mass spec trace makes obvious. Purity plus identity together are what a meaningful analysis looks like. Purity alone is half the picture.

Beyond purity and identity, broader panels address the physical state of the material: appearance, solubility, water content, and contamination screens such as endotoxin, bioburden, and heavy metals. These are the tests that speak to manufacturing hygiene rather than synthesis accuracy. A supplier running a multi-point panel per batch is making a different operational commitment than one running a single purity check on a representative sample and reusing the paperwork.

The last and most overlooked question is whether the COA is lot-specific. A generic document — no lot number, no date, no way to match it to your shipment — proves nothing about the box on your dock. It proves that at some point, some batch was tested.

The verification checklist before any wholesale order

Use these questions on every supplier you evaluate, including this one. The value is in the pattern of answers, not any single response.

Two industry habits are worth naming because they are common and because they are avoidable. The first is treating certificates of analysis as a paid add-on — charging for the document that establishes what you just bought. The second is hiding all pricing behind a quote request so that a buyer cannot compare programs without entering a sales process. Neither practice is illegal; both shift cost and risk onto you, and both are reasonable grounds to keep looking.

How wholesale pricing and order minimums actually work

Wholesale pricing in this sector is built on volume tiers, and the mechanics are consistent even though the numbers differ by supplier and compound. Unit cost falls as committed volume rises, because synthesis, testing, and fulfillment overhead spread across more units. Where suppliers genuinely differ is in how they structure entry: some set a single account-level minimum, others set per-SKU minimums, and others apply tier pricing per order with no ongoing commitment at all. Ask which model applies before you compare any per-unit figure, because the same headline price means different things under different structures.

Margin expectations deserve the same discipline. What a business can realize varies widely with category, order volume, positioning, and the operating costs of the buyer — anyone quoting a specific margin figure to a prospective partner is guessing on your behalf. Build your own model from the tier pricing you are actually offered, then stress-test it against slower-moving SKUs rather than your best sellers.

Also ask how a supplier handles the boring operational cases: short-dated inventory, damaged shipments, lot recalls, and what happens when a compound goes temporarily out of stock. Those answers predict your experience as a partner far better than the initial price sheet.

Compliance questions that belong with your counsel

This section is informational and is not legal advice. Research-use-only compounds sit in a regulatory environment that is genuinely complex, and the answers depend on your business model, your professional licensure, and your jurisdiction.

The questions to bring to your attorney and, where applicable, your state board include: how research-use-only labeling must be maintained through your resale chain; whether your business structure and licensure permit the activity you are planning; what record-keeping obligations attach to compounds you resell; and how your marketing language should be constrained so that it describes research materials rather than anything else. Do not resolve these from a vendor blog, this one included. What a supplier can legitimately give you is documentation, labeling, and traceability. What your counsel gives you is the determination about your own operation — and those two things are not substitutes for each other.

What Real Peptides does differently

Real Peptides tests to 99%+ HPLC purity and runs a 7-panel analysis on every batch, and the resulting certificates of analysis are published where any buyer can verify them independently — before applying, before ordering, and after delivery against the lot received. That is deliberate: a COA that a prospective partner has to request, or pay for, is not doing the job a COA exists to do.

Fulfillment is US-based, with orders shipping in 5–7 days. The Wholesale Partner Program uses a 3-step application, and pricing tiers are disclosed during onboarding rather than held back behind an extended sales conversation. The catalog spans research categories including the growth factor and tissue signaling research collection where CJC-1295 No DAC sits alongside compounds such as Ipamorelin 10mg and Tesamorelin 10mg, each documented on the same basis.

Real Peptides does not provide dosing, reconstitution, or administration guidance for any compound, in any form. These are research materials supplied to businesses, and preparation decisions belong to the qualified party conducting the work.

Where to go from here

If you are evaluating suppliers for a research peptide catalog, run the checklist above against every candidate and see who can answer without friction. For businesses whose model fits — med spas, clinics, telehealth operators, and resellers building their own brand — the Real Peptides Wholesale Partner Program application takes three steps, and the published lab documentation is available for review before you commit to anything.

To look further at how testing and documentation carry across the catalog, the popular peptides and performance and recovery research collections list individual compounds including BPC-157 10mg and TB-500 10mg, each with its own batch analysis.